Twenty pts with various tumor types commenced treatment from Aug 2017 to Aug 2019. The median age was 56 years (27-78 years) and 13 were males. The most common tumor types were adenoid cystic carcinoma (ACC, n=6) and colorectal cancer (n=4).

over 4 years ago

Clinical • P1 data

PD-L1 (Programmed death ligand 1)

KA2507

almost5years

[VIRTUAL] A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11). (ASCO 2020)

Background: The ABC-02 trial provided Level A evidence supporting the use of cisplatin plus gemcitabine as first-line chemotherapy for advanced biliary tract cancer (ABC) [Valle, 2010]. In second line therapy oxaliplatin and 5FU and ivosedinib for IDH1 mutated cancers are options [Lamarca, 2019; Abou-Alfa, 2019] however there remains significant unmet need for patients without actionable alterations...The study received regulatory and ethical approval to proceed in January 2020 and enrolment is in progress. Research Funding: Karus Therapeutics Ltd

almost 5 years ago

Clinical • P2 data

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

cisplatin • gemcitabine • oxaliplatin • fluorouracil topical • KA2507